Welcome to our dedicated page for VEECO INSTRUMENTS SEC filings (Ticker: VECO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veeco Instruments Inc. filings document the regulatory record for a semiconductor process equipment manufacturer serving advanced semiconductor fabrication and packaging applications. Form 8-K reports cover operating and financial results, earnings-release exhibits, material-event disclosures and capital-structure information.
Proxy and annual meeting filings describe Veeco's governance framework, director elections, shareholder voting matters, stock incentive plan proposals, auditor ratification and advisory executive-compensation votes. The filings also provide formal disclosure context for the company's common stock, board oversight, material agreements and risks tied to semiconductor equipment markets and customer demand.
Veeco Instruments and Axcelis Technologies agreed an Acquisition Agreement dated September 30, 2025 under which Axcelis will acquire Veeco in a merger expected to close in 2026, subject to customary closing conditions. Holders of vested Veeco RSUs will have those awards canceled and receive the Merger Consideration for the shares underlying each vested RSU plus any accrued dividend equivalents in cash. Unvested Veeco RSUs will be assumed by Axcelis and converted into Axcelis RSUs covering whole shares based on the Exchange Ratio, with accrued dividend equivalents preserved. Veeco director RSAs that are not vested will become fully vested and canceled with holders receiving the Merger Consideration. Closing conditions include Nasdaq listing approval for Axcelis stock issuance, expiration/termination of the HSR waiting period, PRC regulatory approval, effectiveness of a Form S-4 registration statement, accuracy of material representations and warranties (subject to exceptions), covenants compliance, and absence of a material adverse effect for each company. The filing also references a Fifth Amendment to Veeco's loan agreement and a joint press release dated October 1, 2025.
Insider sale recorded: SVP Adrian Devasahayam reported a sale of 4,014 shares of Veeco Instruments Inc. common stock on 09/23/2025 at a reported price of $30 per share. After the transaction, the reporting person beneficially owned 82,120.208 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Veeco Instruments (VECO) Notice of Proposed Sale (Form 144) reports an intended sale of 4,014 common shares with an aggregate market value of $120,420 to be sold on 09/23/2025 through Fidelity Brokerage Services on NASDAQ. The shares were acquired by the seller via restricted stock vesting in 2021 (2,129 on 03/17/2021; 1,202 on 05/04/2021; 683 on 06/16/2021) as compensation. The filing also discloses a recent sale on 09/15/2025 of 4,046 shares for gross proceeds of $105,196. The form includes the standard representation that the seller has no undisclosed material adverse information.
Insider sale reported: Veeco Instruments SVP Adrian Devasahayam sold 4,046 shares of Veeco common stock on 09/15/2025 at $26.00 per share, reducing his beneficial ownership to 86,134.208 shares. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Form 144 notice for proposed sale of securities by a party associated with Veeco Instruments, Inc. The filing reports an intended sale of 4,046 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $105,196.00, to be offered on or about 09/15/2025 on the NASDAQ. The filing states 60,161,823 shares outstanding for the class. The shares were acquired by the seller via restricted stock vesting on 09/01/2021 (818 shares) and 09/14/2021 (3,228 shares) and were paid as compensation. The filing reports Nothing to Report for sales during the past three months. Several filer and issuer identification fields in the form are blank in the provided content.
Insider sale and correction: William John Miller, identified as both CEO and a director of Veeco Instruments Inc (VECO), reported a disposition of 25,000 shares of Veeco common stock at $25.00 per share, leaving him with 539,543 shares beneficially owned after the transaction. The Form 4/A amends a prior filing to correct the number of shares shown in Box 5; the amendment states no additional shares were sold beyond those disclosed in the original report. The filing also indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1 affirmative defense conditions, which typically documents pre-arranged sales.
Veeco Instruments insider transaction: William John Miller, identified as the company's CEO and a director, reported a sale of 25,000 shares of Veeco Instruments Inc. (VECO) on 09/09/2025 at a price of $25 per share. After the reported sale, Mr. Miller beneficially owned 470,671 shares. The filing indicates the transaction was made pursuant to a Rule 10b5-1 trading plan. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Veeco Instruments Inc. (VECO) filed a Form 144 reporting a proposed sale of 25,000 shares of common stock through Wells Fargo Clearing Services with an aggregate market value of $624,493.00. The filing lists the approximate outstanding shares as 60,161,823 and an intended sale date of 09/09/2025 on Nasdaq.
The shares to be sold were acquired in 2024 as grants: 7,138 shares on 03/13/2024, 6,787 on 03/12/2024 and 11,075 on 03/18/2024. The filer indicates no sales in the past three months and certifies no undisclosed material adverse information. This is a routine Rule 144 notice describing a proposed sale by a person whose holdings were obtained via issuer grants.
Manulife and its investment-management subsidiaries reported beneficial ownership stakes in Veeco Instruments common stock. Manulife Investment Management (US) LLC holds 3,195,268 shares, representing 5.48% of the 58,292,152 shares outstanding cited in the filing. Manulife Investment Management Limited holds 19,763 shares (about 0.03%), and through its parent-subsidiary relationship, Manulife Financial Corporation may be deemed to beneficially own these holdings.
The Schedule 13G/A clarifies voting and dispositive powers: the reporting entities state sole voting and sole dispositive power over the shares listed. The filing is a disclosure of institutional ownership crossing the 5% threshold by MIM (US) and documents the corporate and regulatory identities of the reporting persons.